Skip to main
HURA

HURA Stock Forecast & Price Target

HURA Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

TuHURA Biosciences is currently valued at $636M using a DCF-based methodology, with a target price of $10 per share. Risks associated with this valuation include potential negative clinical results, delays in pipeline advancement, difficulty obtaining regulatory approvals, competition from other checkpoint inhibitors, and potential dilution in the medium-to-long term. However, as a phase 3 clinical stage company with a diverse portfolio of technologies, TuHURA Biosciences has the potential to overcome these risks and experience significant growth in the future.

Bears say

TuHURA Biosciences is currently facing a number of significant challenges, including a recent decline in stock price, which may be attributed to a lack of positive news and updates on their clinical trials, as well as the high costs associated with their research and development efforts. These challenges may hinder the company's ability to meet their upcoming value inflection points and could lead to delayed or disappointing results, making their stock a risky investment option.

HURA has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of TuHURA Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About TuHURA Biosciences Inc (HURA) Forecast

Analysts have given HURA a Strong Buy based on their latest research and market trends.

According to 3 analysts, HURA has a Strong Buy consensus rating as of Jun 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $9, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $9, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

TuHURA Biosciences Inc (HURA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.